A causal role for the human tumor antigen preferentially expressed antigen of melanoma in cancer
MT Epping, R Bernards - Cancer research, 2006 - AACR
MT Epping, R Bernards
Cancer research, 2006•AACRTumor antigens are of interest as diagnostic and prognostic markers and potential
therapeutic targets. The tumor antigen preferentially expressed antigen of melanoma
(PRAME) is frequently overexpressed in a wide variety of cancers and is a prognostic
marker for clinical outcome. It has been shown recently that PRAME functions as a repressor
of retinoic acid signaling. Here, we discuss this novel insight in the context of the increasing
interest in tumor antigens as targets for therapy.(Cancer Res 2006; 66 (22): 10639-42)
therapeutic targets. The tumor antigen preferentially expressed antigen of melanoma
(PRAME) is frequently overexpressed in a wide variety of cancers and is a prognostic
marker for clinical outcome. It has been shown recently that PRAME functions as a repressor
of retinoic acid signaling. Here, we discuss this novel insight in the context of the increasing
interest in tumor antigens as targets for therapy.(Cancer Res 2006; 66 (22): 10639-42)
Abstract
Tumor antigens are of interest as diagnostic and prognostic markers and potential therapeutic targets. The tumor antigen preferentially expressed antigen of melanoma (PRAME) is frequently overexpressed in a wide variety of cancers and is a prognostic marker for clinical outcome. It has been shown recently that PRAME functions as a repressor of retinoic acid signaling. Here, we discuss this novel insight in the context of the increasing interest in tumor antigens as targets for therapy. (Cancer Res 2006; 66(22): 10639-42)
AACR